Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as the …
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as the …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
Phase 3 ARTISTRY-1 and ARTISTRY-2 data support an NDA for a single-tablet HIV regimen combining a capsid inhibitor …
Four-year open-label extension data for zorevunersen reinforce the antisense oligonucleotide’s disease-modifying potential in SCN1A-linked epilepsy, as the pivotal …
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal lobe …
The British pharma giant’s third major deal of 2026 secures two FDA Breakthrough Therapy-designated kinase inhibitors and a …
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate wins two new indications based on pivotal DESTINY-Breast11 and DESTINY-Breast05 trials, reshaping …
The stealth-mode startup emerges with a pipeline targeting focal epilepsy, schizophrenia, tinnitus, and reversible encephalopathy — all acquired …
BioMarin Pharmaceutical has announced positive pivotal Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, the most …
Already a subscriber? Log in